Product Details
| Product Name:
SC99 |
CAS No.:
882290-02-0 |
| Purity:
99.56% |
Supply Ability:
10g |
| Release date:
2025/07/25 |
Product Introduction
Bioactivity
| Name | SC99 |
| Description | SC99 is a selective inhibitor of JAK2-STAT3 activation. SC99 downregulates the expression of STAT3-modulated genes.SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities |
| In vitro | SC99 inhibited the phosphorylation of JAK2 and STAT3 in human platelets but had no effects on the phosphorylation of AKT, p65 or Src, all of which are involved in platelet activation.?SC99 inhibited human platelet aggregation induced by collagen and thrombin in a dose-dependent manner.?SC99 inhibited thrombin-induced P-selectin expression and fibrinogen binding to single platelets.?Moreover, SC99 inhibited platelet spreading on fibrinogen and clot retraction mediated by outside-in signaling.?SC99 inhibited platelet aggregation in mice but it did not significantly prolong the bleeding time.?SC99 inhibited platelet activation and aggregation as a STAT3 inhibitor.?This agent can be developed as a promising treatment for thrombotic disorders. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 82 mg/mL (243.94 mM), Sonication is recommended.
|
| Keywords | STAT3 | STAT | SC-99 | SC99 | SC 99 | pocket | platelet | phosphorylation | orally | OPM2 | myeloma | multiple | mTOR | Janus kinase | JAK2 | JAK | Inhibitor | inhibit | ERK | c-Src | ATP-binding | Apoptosis | anti-thrombotic | anti-myeloma | AKT | aggregation | activation |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | JAK-STAT Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1400974-23-3
$128.00 / 5mg
-
CAS:1202884-94-3
$0.00 / 1mg
-
CAS:108825-65-6
$30.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States